Luven Diagnostic

Luven Diagnostic

Created using Figma
Created using Figma
Promoting a unique cancer diagnosis technology.
Jan 15, 2018
Feb 28, 2018
100% completed
$26 350
100% goal completed
  • 290 LVN
    1 ETH
Dec 8, 2017
Dec 29, 2017
100% completed
Raised funds - no Data
  • 290 LVN
    1 ETH
Token Details
Accepted Currencies
Company Details
Registered Country
Additional Details

About Luven Diagnostic

The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy.

The LUVEN technology allows to diagnose the disease at its early stages, thus, giving a chance to thousands of people to prevent its further development.

For more than 20 years the Ukrainian scientists have been developing a diagnostic method based on cyto-morphological and cyto-biophysical properties of the buccal epithelial cells. In 2004 at Fenix Cancer Research Center, they continued their research and, finally, came up and implemented an experimental method. A new method of biomaterial analysis allowed to establish a cancer diagnosis at its early stages and to assess predisposition to cancer. A great success in this medical field opened a door to new possibilities,including cancer prevention and therapy. The longstanding scientific research in this field culminated in development of The Luven diagnostic system.

Why is it critical to detect cancer in its early stage?
Around 10 mln people worldwide are annually diagnosed with cancer, with every third patient dying from it. One of the main reasons of such a high mortality rate is late diagnosis.

According to statistics:

  • after treatment in stage 1 cancer — around 93% of patients survive;
  • stage 2 cancer — around 75% survive;
  • stage 3 cancer — 55% survive;
  • stage 4 cancer — only 13% survive;

This is why one should get a check-up as often as possible, thus preventing the disease progression.

Regardless of the rapid development of modern medicine and biology cancer, annually, takes millions of human lives. One cancer patient, worldwide, dies from this disease every 30 seconds.

The key to successful cancer treatment is early diagnosis.

Our History

The development of this method started in early 1983 at the research institute, chair for genetics. Based on the cellular theory by Rudolf Vichow, a team of scientists was working on a diagnostic method and studying buccal cells. Ms. Galina Shchukina, a genetic scientist and cytologist, was at the head of the scientific research. She conducted an in-depth study of scientific papers describing a new biophysical concept of the gene activity regulation based on the role of relationship between homologous chromosomes and genome. Together with Mr. Alexander Shchukin, a nuclear physicist, they invented an ion trap allowing to estimate bioelectric charge of cells. Further research and studies of this concept laid the basis for a new diagnostic method born in 2004, according to which any changes in the human body reflect on cells, including buccal epithelial cells. It was the first milestone in the development of LUVEN a unique diagnostic and treatment system. As of today, this method allowed to collect statistical data on tests of more than twenty thousand of patients.

Why is it lucrative?

Cancer research is an acute social problem, in view of this they cast a veil on profits of medical companies. However, in-vitro diagnostics, and particularly cancer diagnostics, is a huge and most rapidly developing sector, with the potential global market of DNA cancer tests worth about $20 bn.

Unlike the majority of projects involving ICO, our company has already completed 90% of the whole thing. The presale period starts on November 15 until December 6, 2017. The token sale is planned from January 15 to February 28, 2018.


  • already completed 90% of the project.

Token holders have two opportunities:

  • receiving a part of the company income
  • exchanging their tokens for testing services with a 30% discount, using or selling them to wholesale customers

Technical Info

Ethereum ERC20 standard token.

Luven Diagnostic Roadmap

  • 1983

  • Development ofthe cancer diagnostic method started, based on the study of buccal cells (cells from the inside ofthe cheek)
  • 2004

  • A cytomorphobiologial diagnostic method appeared which formed the basis ofthe diagnostic complex
  • 2010

  • Team expansion. A commercial enterprise promoting the LUVEN trademark was established. The software automating a part ofthe diagnostic procedure was created.
  • 2014

  • The diagnostic method was patented, completion of the clinicaltrials, creation ofthe software diagnostic complex presented at two international medical exhibitions “The 5th International Medical Forum” and “Health Care 2014”. Opening first franchise outlets.
  • Read More
  • 2015

  • In five months after launching a franchise, the contracts were signed with more than twenty outlets, half of which have already run tests on more than two thousand patients. Suspension of activities for a time allowing technology enhancement.
  • 2016 - 2017

  • Software enhancement, additional clinicaltrials. Optimizing a big number ofthe system algorithms
  • September - October 2017

  • Preparing and starting a preICO aimed at fundraising for the software enhancement, legal costs and operational expenses ofthe project
  • January 2018

  • Starting an ICO
  • 2018

  • Further software enhancement, signing contracts with clinics worldwide for conducting clinicaltrials, opening a research center in Austria. Initiating certification ofthe method in the European Union and Eurasian Union
  • 2019

  • Opening 20 new labs in the European Union and Eurasian Union, incorporating a blockchain and developing a domestic exchange for token sale, working on the optical recognition of incoming images ofthe cell, creating a database of patients and their test results for monitoring tendencies and informing patients on the necessity of being diagnosed
  • 2020

  • Starting clinicaltrials and certification in the USA and Asia
  • 2021

  • Developing home gadgets (a home lab) for running tests on the entire family at any time, launching the product.


1 315
13 613
1 315
13 613
1 688
30 Days Growth:

Luven Diagnostic Team

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Alexander Danilchenk...
Nikolay Shchukin
Postgraduate Student of Chair for Biomedical Engin...
Aleksander Shchukin
Nuclear Physician
Galina Shchukina
Geneticist & Cytologist
Grigory Evglevskiy
Alexander Kamensky
Principal Software Engineer
Yana Ivchenko
PR Manager

Luven Diagnostic Last News

5.0 13
ICO Profile Vision Activity Potential Product Team
  • Because there may be time differences in information updates, accurate information about each ICO project should be verified through its official website or other communication channels.
  • This information is not a suggestion or advice on investing in ICO funding. Please thoroughly investigate the relevant information yourself and decide on ICO participation.
  • If you think there are issues or problems to be corrected on this content, or if you would like to submit your own ICO project to be listed, Please email us.
Please read the disclaimer and risk warning. Show disclaimer and risk warning.
Planning an ICO? We can help with a wide range of support for all stages of your ICO